GCP
MXCT icon

GSA Capital Partners’s MaxCyte MXCT Stock Holding History

GSA Capital Partners’s Portfolio MXCT Stock Details MXCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$684K Buy
555,944
+539,456
+3,272% +$538K 0.04% 778
2026
Q1 		$12K Buy
+16,488
New +$15.4K ﹤0.01% 1652

Other funds holding MXCT

CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return
VP
Vitruvian Partners London, United Kingdom $201M AUM 10.44% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
MA
Mudita Advisors London, United Kingdom $481M AUM 73.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BFM
Brooklands Fund Management London, United Kingdom $128M AUM
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
CCM
Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

GSA Capital Partners's MXCT Position: Q2 2026 in Review

GSA Capital Partners increased its MaxCyte (MXCT) stake by 3,272% in Q2 2026, buying an estimated $538K and bringing the position to 555,944 shares worth $684K. The position accounts for 0.04% of the portfolio, ranked #778.

GSA Capital Partners first reported a position in MXCT in Q1 2026 and has held it in 2 quarters since. 122 funds tracked by Wall St. Rank hold MXCT as of Q2 2026.

  • GSA Capital Partners held 555,944 shares of MaxCyte worth $684K as of Q2 2026.
  • GSA Capital Partners bought 539,456 MaxCyte shares in Q2 2026, an estimated $538K.
  • MaxCyte made up 0.04% of GSA Capital Partners's portfolio in Q2 2026, its #778 holding.
  • GSA Capital Partners first reported a position in MaxCyte in Q1 2026 and has held it in 2 quarters since.
  • 122 funds tracked by Wall St. Rank held MaxCyte as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.